Evidence map›Paper›PMID 41790170›Full record

ArticleGeroScience2026

CSF elevated Tau and P-Tau and normal Aβ42 mainly corresponds to Alzheimer's disease with dementia with Lewy bodies.

Olivier Bousiges, Benjamin Cretin, Lisa Battista, Caroline Schaeffer-Agalède, Nathalie Philippi, Lola Hamied, Alix Ravier, Catherine Demuynck, Candice Muller, Frédéric Blanc

Abstract read
PubMed Publisher
In one paragraph

Article in GeroScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Olivier BousigesUniversity of Strasbourg and CNRS, ICube Laboratory UMR 7357 and FMTS (Fédération de Médecine Translationnelle de Strasbourg), IMIS Team, 4, Rue Kirschleger, 67085, Strasbourg, France. olivier.bousiges@chru-strasbourg.fr.ORCID http://orcid.org/0000-0001-6786-3191
Benjamin CretinUniversity Hospitals of Strasbourg, CM2R (Research and Resources Memory Center), Day Hospitals, Service of Gerontology Mobile-Neuro-Psy-Research, GeRMINED Department, 21 Rue David Richard, 67000, Strasbourg, France.
Lisa BattistaUniversity of Strasbourg and CNRS, ICube Laboratory UMR 7357 and FMTS (Fédération de Médecine Translationnelle de Strasbourg), IMIS Team, 4, Rue Kirschleger, 67085, Strasbourg, France.
Caroline Schaeffer-AgalèdeLaboratory of Biochemistry and Molecular Biology, University Hospital of Strasbourg, Hautepierre Hospital, Avenue Molière, 67098, Strasbourg Cedex, France.
Nathalie PhilippiUniversity Hospitals of Strasbourg, CM2R (Research and Resources Memory Center), Day Hospitals, Service of Gerontology Mobile-Neuro-Psy-Research, GeRMINED Department, 21 Rue David Richard, 67000, Strasbourg, France.
Lola HamiedLaboratory of Biochemistry and Molecular Biology, University Hospital of Strasbourg, Hautepierre Hospital, Avenue Molière, 67098, Strasbourg Cedex, France.
Alix RavierUniversity Hospitals of Strasbourg, CM2R (Research and Resources Memory Center), Day Hospitals, Service of Gerontology Mobile-Neuro-Psy-Research, GeRMINED Department, 21 Rue David Richard, 67000, Strasbourg, France.
Catherine DemuynckUniversity Hospitals of Strasbourg, CM2R (Research and Resources Memory Center), Day Hospitals, Service of Gerontology Mobile-Neuro-Psy-Research, GeRMINED Department, 21 Rue David Richard, 67000, Strasbourg, France.
Candice MullerUniversity Hospitals of Strasbourg, CM2R (Research and Resources Memory Center), Day Hospitals, Service of Gerontology Mobile-Neuro-Psy-Research, GeRMINED Department, 21 Rue David Richard, 67000, Strasbourg, France.
Frédéric BlancUniversity of Strasbourg and CNRS, ICube Laboratory UMR 7357 and FMTS (Fédération de Médecine Translationnelle de Strasbourg), IMIS Team, 4, Rue Kirschleger, 67085, Strasbourg, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Some cerebrospinal fluid (CSF) Alzheimer's disease (AD) biomarker profiles are difficult to interpret. We investigated one such case: normal Aβ42 and pathologically increased levels of Tau and P-Tau (Tau&PTau profile). We first extracted details of 184 patients with a Tau&PTau profile who had been followed up in Strasbourg, France (cohort 1) and whose diagnosis has been reviewed. Secondly, we recovered and analyzed the AD biomarker results and clinical diagnoses of a cohort of 1199 patients also followed up in Strasbourg (cohort 2). In cohort 1, 57% of patients were patients with comorbidity: they had both Alzheimer's disease and dementia with Lewy bodies (DLB) (AD+DLB). In cohort 2, among patients with a Tau&PTau profile: between 39.6 and 53.1% had comorbidity with AD, with more than half of the comorbidities being DLB. In cohort 2, among patients with AD+DLB, the majority (64.4%) had a Tau&PTau profile. These results show that patients with AD+DLB comorbidity mainly have a Tau&PTau profile. These results are relatively counterintuitive, given that AD and DLB are two diseases in which it is common, even systematic, to find a CSF Aβ42 decrease. However, the combination of the two diseases, or more broadly, AD comorbidity, indicates higher levels of Aβ42 than in pure AD.

Indexed as

Alzheimer’s diseaseComorbiditiesCSF atypical profileDementia with Lewy bodiesNormal Aβ42, pathological Tau, and P-Tau (A-T+N+)

Identifiers

PMID41790170

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.